© 2021 Solid Biosciences1 Solid Biosciences Corporate OverviewOctober 2021 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's IGNITE DMD clinical trial, ability of the Company to continue dosing patients in the IGNITE DMD trial, the implication of interim clinical data, the safety or potential treatment benefits of SGT-001 in patients with Duchenne, the Com ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) WASHINGTON, DC 20549 Delaware 90-0943402 (State or other jurisdicti ...

Financial Data and Key Metrics Changes - In Q1 2021, the company closed a public offering resulting in gross proceeds of approximately $143.8 million before deductions, strengthening its balance sheet [33] - The company ended the quarter with $268.5 million in cash and cash equivalents, which is expected to fund operating expenses into Q4 2022 [34] Business Line Data and Key Metrics Changes - Two patients were dosed in the IGNITE DMD trial this quarter using SGT-001 produced with an improved manufacturing process [7] - Patient 8 experienced a serious adverse event (SAE) but has since been discharged, with lab values trending towards normal [7][13] Market Data and Key Metrics Changes - The company is advancing its preclinical pipeline with the nomination of SGT-003 as the next development candidate, which combines a novel capsid and proprietary microdystrophin construct [9][30] Company Strategy and Development Direction - The company is focused on expanding its pipeline with differentiated gene therapies, including SGT-003, which aims to enhance delivery to muscle cells [10][30] - Collaboration with Ultragenyx is ongoing to optimize candidate vectors for additional Duchenne gene therapies [31][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term potential of SGT-001 based on encouraging long-term biopsy data and clinical biomarker trends [26][37] - The company remains committed to the Duchenne community and aims to advance therapies that improve patient lives [38] Other Important Information - The company is working closely with its Data Safety Monitoring Board (DSMB) to evaluate data and ensure patient safety before continuing dosing in the IGNITE DMD trial [12][14] Q&A Session Summary Question: Long-term expression data and its correlation with clinical benefits - Management acknowledged the correlation observed but emphasized the need for more data to establish specific relationships [42][44] Question: Dosing path for additional patients and details on SAE - Management confirmed that the SAE was an inflammatory response and that they are working with the DSMB to evaluate the situation before proceeding with further dosing [47][48] Question: Additional information on Patient 8's inflammatory response - Management indicated that they are still evaluating the specifics of Patient 8's response and have seen laboratory evidence of complement activation in all treated patients [51][53] Question: Timeline for additional functional data from Patients 7 and 8 - Management stated that functional data from Patient 7 will take time to analyze due to the influence of steroids and has not provided a specific timeline [63] Question: Factors influencing long-term data variability among patients - Management noted that variability is expected in biological assays and that they are investigating potential mechanisms behind the differences observed [65][66] Question: Potential changes to the protocol to reduce inflammatory events - Management is exploring various options for protocol modifications to enhance patient safety, but no specific changes have been determined yet [75] Question: Sharing of SAE details with FDA and DSMB - Management confirmed that they have shared details of the SAE with both the FDA and DSMB and are in ongoing discussions [77]

WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission File Number: 001-38360 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 90-0943402 (State or other jurisdict ...

SGT-001 Interim Clinical Results From IGNITE-DMD Ilan Ganot, Co-founder, President, and CEO March 15, 2021 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's IGNITE DMD clinical trial, ability of the Company to continue dosing patients in the IGNITE DMD trial, the implication of interim clinical data, the safety or potential treatment benefits of SGT-001 in ...

FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38360 Solid Biosciences Inc. (Exact name of Registrant as specified in its Charter) Delaware 90-0943402 (State or other jurisdiction ...

Solid Biosciences Inc (NASDAQ:SLDB) Q3 2020 Earnings Conference Call November 5, 2020 8:30 PM ET Company Participants Jennifer Ziolkowski – Chief Financial Officer Ilan Ganot – Co-Founder, President and Chief Executive Officer Joel Schneider – Chief Technology Officer Cathryn Clary – Acting Chief Medical Officer Conference Call Participants Mark Connolly – Credit Suisse Joseph Schwartz – SVB Leerink Operator Ladies and gentlemen, thank you for standing by and welcome to the Solid Biosciences Update Call. At ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 90-0943402 (State or other juris ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 90-0943402 (State or other jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38360 Solid Biosciences Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 90-0943402 (State or other jurisdict ...